Objective To discuss the curative effects and security of Edaravone combined Edaravone low molecular heparin on treating progressive cerebral infarction ( PCI). Methods 100 patients with progressive cerebral infarction were divided into two groups randomly, the observation group (50cases) and control group (50cases) of the same basic treatment. The observation group were treated with Edaravone 30 mg intravenousdrip twice a day for 14d. Meanwhile, low molecular heparin sodium 5000IU per 12 hours for 7d. Control group using the aspirin 300mg/d oral for 3 days, then subsequently 100mg/d. Platelet( PLT) tactivated partical prothrom-plastin time ( APTT) 、Fibrinogen (Fg) 、Neunspecific eolase( NSE) and Neural Functional Impairment Scoring were tested before and after treatment in the two groups. Results The cure rate and the effective rate of the observation group were obviously higher than those of the control group ( P < 0. 05). And without obvious advers reaction in two group. Conclusion Edaravone combined with low molecular heparin is safe and effective on progressive cerebral infarction.%目的 探讨依达拉奉联合低分子肝素治疗进展性脑梗死的疗效及其安全性.方法 100例急性进展性脑梗死患者随机分为观察组(50例)和对照组(50例),两组基础治疗相同,观察组采用依达拉奉30mg加入生理盐水100mL·d-2,静滴,共14d,低分子肝素钠5000IU·12h-1,脐周皮下注射,共7d;对照组应用阿司匹林300mg·d-1口服,3d后减为100mg·d-1.两组治疗前后分别检测血小板(PLT)、部分凝血酶原时间(APTT)、纤维蛋白原(Fg)、血清神经元特异性烯醇化酶(NSE)及对临床神经功能缺损程度评分进行评定.结果 观察组在治愈率、总有效率方面明显高于对照组(p＜0.05).且观察组血清NSE明显下降(P＜0.05).两组均无明显的不良反应.结论 依达拉奉联合低分子肝素治疗进展性脑梗死安全有效.
展开▼
